Clinical Trials
The Doctors at Pacific Northwest Retina are dedicated to providing the best, most up-to-date treatments for our patients. To this end, our doctors have participated in several clinical trials testing new drugs for Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusions, Vitreomacular Traction, and Ocular Melanoma.
Listed below are the active trials in which we are participating. Some of these trials are actively enrolling patients and others have completed enrollment and the patients are in the follow-up stage of the trial. If you would like to learn more about any of these trials, please send your questions to info@pnwretina.com or by calling any of our locations:
Bellevue: 206-215-3561
Burlington: 360-205-5417
Silverdale: 360-307-0300
Now enrolling at our Bellevue, Burlington and Silverdale locations.
Enrolling Now
- A Multicenter Platform Study on the Safety, Tolerability, Bioactivity, and Pharmacokinetics of Intravitreal Therapies in Retinal Vascular and Inflammatory Diseases.
- Offered at our Bellevue Location.
- A Phase 3 randomized, controlled, assessor masked trial comparing a single course and two repeat courses of treatment with AU-011 to 125I brachytherapy in subjects with small to medium choroidal melanoma (CM).
- Offered at our Bellevue and Burlington Location.
- Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862
- Offered at our Bellevue location.
- A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants With Neovascular Age-Related Macular Degeneration
- Offered at our Burlington location
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)
